Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...

Like many pharma stocks, Eli Lilly (NYSE: LLY) offers investors a bit of safety -- and it's an element you can count on ...

Eli Lilly’s rising fortunes tied to its weight loss and diabetes drugs led to a nine-figure payday for its top executive.

Eli Lilly plans to launch its blockbuster diabetes and weight-loss drug in major emerging markets like India, Brazil and ...

A federal judge has effectively ended the ability of compounding pharmacies to make their own copies of Eli Lilly’s weight ...

FDA is aware that some patients and health care professionals may look to unapproved versions of GLP-1 – glucagon-like peptide-1 receptor agonists – drugs, including semaglutide and tirzepatide, as an ...

Eli Lilly (LLY) joins hands with Magnet Biomedicine in a deal worth up to $1.25B to develop cancer drugs using Magnet's innovative TrueGlue platform. Read more here.

Investors are bullish on Eli Lilly and Company (NYSE:LLY) due to its in-demand GLP-1 drugs, used to treat diabetes and ...

The partnership comes as telehealth companies grapple with restrictions on the sale of some compounded GLP-1s.

It's hard to argue with the kinds of results Eli Lilly ( LLY 1.71%) has produced over the past five years. The company has been one of the best-performing pharmaceutical giants, with its shares ...

Danish drugmaker Novo Nordisk said Wednesday that it will drop prices 23% for all doses of Wegovy. The new monthly price of ...